Bio-Rad Laboratories
BIO
358.90
-8.60
-2.34%
Bio-Rad Laboratories
US · BIO
#1479 by market cap
Listed 1970
358.90
-8.60
-2.34%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
H.C. Wainwright Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $90Market Newswire · 2026/11/13
-
Bio-Rad Laboratories | 8-K: Bio-Rad Reports Third -Quarter 2026 Financial ResultsSEC · 2026/11/5
-
Company notice
Weiguang Bio: Legal Opinion of King & Wood Mallesons (Shenzhen) on the Second Extraordinary Shareholders' Meeting of Shenzhen Weiguang Biological Products Co., Ltd. for 2026SZSI · 2026/11/14
-
Company notice
Zhijiang Bio: Legal Opinion of Zhejiang TianCe Law Firm Regarding the Second Extraordinary Shareholders' Meeting of Shanghai Zhijiang Biotechnology Co., Ltd. for 2026SZSI · 2026/11/14
-
Company notice
ADAPTIN BIO INC. | 10-Q: Quarterly reportSEC · 2026/11/14
-
Rating change
Freedom Capital Markets Initiates INmune Bio(INMB.US) With Buy Rating, Announces Target Price $2.5Market Newswire · 2026/11/13
-
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $440Market Newswire · 2026/11/5
-
Rating change
Maxim Group Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8Market Newswire · 2026/11/13
-
Company notice
Bio-Thera Solutions: Legal Opinion of Fangda (Guangzhou) Law Firm, Shanghai, Regarding the Third Extraordinary Shareholders' Meeting of Bio-Thera Solutions Ltd. in 2026SZSI · 2026/11/14
-
Rating change
CCORF Maintains TELA Bio(TELA.US) With Buy Rating, Maintains Target Price $2Market Newswire · 2026/11/12
-
Bio-Rad Laboratories Affirms FY2026 Sales Guidance of $2.506B-$2.596B Vs $2.588B EstBenzinga · 2026/11/5
-
Bio-Rad Laboratories | 10-Q: Q3 2026 Earnings ReportSEC · 2026/11/5
-
Company notice
Kechian Bio: Announcement by Wuhan Kechian Bio Co., Ltd. Regarding the Convening of the Third-Quarter 2026 Earnings Conference CallSZSI · 2026/11/14
-
Rating change
Goldman Sachs Maintains Braveheart Bio(BRVE.US) With Buy Rating, Raises Target Price to $49Market Newswire · 2026/11/12
-
Bio-Rad Laboratories Q3 Adj. EPS $2.65 Beats $2.23 Estimate, Sales $656.400M Beat $649.950M EstimateBenzinga · 2026/11/5
-
Rating change
Piper Sandler Maintains TELA Bio(TELA.US) With Hold Rating, Maintains Target Price $1Market Newswire · 2026/11/11
-
Rating change
Leerink Partners Maintains Belite Bio(BLTE.US) With Buy Rating, Raises Target Price to $215Market Newswire · 2026/11/13
-
Rating change
H.C. Wainwright Maintains Belite Bio(BLTE.US) With Buy Rating, Maintains Target Price $245Market Newswire · 2026/11/13
-
Rating change
B. Riley Securities Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7Market Newswire · 2026/11/13
-
Rating change
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $8Market Newswire · 2026/11/12
-
Rating change
Argus Research Downgrades Bio-Techne(TECH.US) to Sell RatingMarket Newswire · 2026/10/27
-
Rating change
Piper Sandler Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $40Market Newswire · 2026/10/30
-
Rating change
H.C. Wainwright Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7Market Newswire · 2026/10/29
-
Rating change
Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $25Market Newswire · 2026/10/27
-
Rating change
Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $25Market Newswire · 2026/10/26
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Bio-Rad Laboratories discussion 0 comments